ROKU and NFLX dominate streaming in different ways, with platform scale and content investment shaping their paths ahead.

JD.com's food delivery push is growing fast, but soaring marketing costs and widening losses raise questions about when margins can catch up.

LOS ANGELES, Dec. 26, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Alexandria Real Estate Equities, Inc. (“Alexandria” or “the Company”) (NYSE: ARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 27, 2025 and October 27, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before January 26, 2026.

If you don't buy the AI bubble fears and think the increased skepticism over some of the names powering the technology, it might be time to get just a bit more greedy to start 2026 off on the right track.

PINS leverages AI to boost content discovery, personalization, and ad performance, making ideas easier to find and shop.

Medicus Pharma (NASDAQ:MDCX) earlier this week shared details of a planned collaboration with Reliant AI to improve clinical trial execution through artificial intelligence. The company's chief medical officer, Dr Faisal Mehmud, said the collaboration will focus initially on supporting the development of Teverelix, a compound that was acquired through Medicus's takeover of Antev during the summer.

BitMine Immersion Technologies (BMNR) has transformed into the world's largest public Ethereum treasury, holding over 4 million ETH worth $12 billion. BMNR trades at 0.80x book value, a 20% discount to NAV, with the stock consolidating near critical $25-28 support after a 170% gap-up in July 2025. Technical setup targets $131. The MAVAN staking solution, launching in early 2026, could convert BMNR's passive ETH holdings into a yield-generating asset, supporting income and dividends.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are up 2.2% to trade at $7.06 at last check.

Rob Rowe, head of global strategy at Citi Research, joins ‘Money Movers' to discuss his 2026 outlook, the firm's S&P 500 target, and more

Active and passive investing strategies are pit against each other all the time despite appearing together in countless portfolios.

Wind energy is gaining momentum as rising U.S. capacity, AI-driven power demand and clean energy investments accelerate the transition. Stocks like NEE, CEG, PCG and ACA are attractive long-term picks.

Oracle (NYSE:ORCL ) looked set to be the newest addition to the $1 trillion club just a few months back in September, where its valuation topped $877 billion.

Visa Inc. and Mastercard Incorporated form a resilient duopoly benefiting from scale, network effects, and secular digital payment growth. V edges out MA with higher margins, a cleaner balance sheet, and a lower valuation, supporting a Strong Buy rating for Visa versus Buy for Mastercard. Both companies are protected from credit risk, generate robust free cash flow, and return significant capital to shareholders through buybacks and dividends.

LOS ANGELES, Dec. 26, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Jayud Global Logistics Limited (“Jayud” or “the Company”) (NASDAQ: JYD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 21, 2023 and April 30, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before January 20, 2026.

Nvidia ( NASDAQ:NVDA ) has become the face of the AI revolution.

As we come to the close of 2025, tech stocks are gaining pace, and they've remained one of the best performing in the industry.

Since early August, the world's most valuable pharmaceutical stock, Eli Lilly and Company NYSE: LLY, has put on a stellar performance. After tanking 14% on Aug. 7 due to poor clinical trial results, shares have gained a whopping 71% year-to-date.

COIN and CME both target growth, but only one is gaining ground as they expand beyond trading into new digital frontiers.

Qualcomm's handset revenues surge 14% on strong Snapdragon demand, even as competition, trade tensions, and in-house chips challenge its smartphone business.

Microsoft and Oracle both ride enterprise cloud and AI demand, but differences in growth, capex, and execution shape which stock offers better upside.